IL160878A0 - Imidazo (4,3-e)-1,2,4-triazolo (1,5-c) pyrimidines as adenosine a2a receptor antagonists - Google Patents
Imidazo (4,3-e)-1,2,4-triazolo (1,5-c) pyrimidines as adenosine a2a receptor antagonistsInfo
- Publication number
- IL160878A0 IL160878A0 IL16087802A IL16087802A IL160878A0 IL 160878 A0 IL160878 A0 IL 160878A0 IL 16087802 A IL16087802 A IL 16087802A IL 16087802 A IL16087802 A IL 16087802A IL 160878 A0 IL160878 A0 IL 160878A0
- Authority
- IL
- Israel
- Prior art keywords
- triazolo
- pyrimidines
- imidazo
- adenosine
- receptor antagonists
- Prior art date
Links
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 title 1
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32956701P | 2001-10-15 | 2001-10-15 | |
PCT/US2002/032630 WO2003032996A1 (en) | 2001-10-15 | 2002-10-11 | Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
IL160878A0 true IL160878A0 (en) | 2004-08-31 |
Family
ID=23286007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16087802A IL160878A0 (en) | 2001-10-15 | 2002-10-11 | Imidazo (4,3-e)-1,2,4-triazolo (1,5-c) pyrimidines as adenosine a2a receptor antagonists |
Country Status (16)
Country | Link |
---|---|
US (1) | US6653315B2 (de) |
EP (1) | EP1435960B1 (de) |
JP (2) | JP4545437B2 (de) |
KR (1) | KR100687954B1 (de) |
CN (1) | CN100421663C (de) |
AR (1) | AR037243A1 (de) |
AU (1) | AU2002340184B2 (de) |
CA (1) | CA2463598C (de) |
HU (1) | HUP0401777A3 (de) |
IL (1) | IL160878A0 (de) |
MX (1) | MXPA04003474A (de) |
MY (1) | MY124864A (de) |
NZ (1) | NZ531761A (de) |
PE (1) | PE20030477A1 (de) |
WO (1) | WO2003032996A1 (de) |
ZA (1) | ZA200402812B (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002352933A1 (en) * | 2001-11-30 | 2003-06-17 | Schering Corporation | [1,2,4]-triazole bicylic adenosine A2a receptor antagonists |
US20040127510A1 (en) * | 2002-04-16 | 2004-07-01 | Heintzelman Geoffrey R. | Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods |
DE60335294D1 (de) | 2002-12-19 | 2011-01-20 | Schering Corp | Dlung des extrapyramidalen syndroms |
TWI355381B (en) | 2003-04-23 | 2012-01-01 | Schering Corp | 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-tri |
BRPI0411120A (pt) * | 2003-06-10 | 2006-07-18 | Kyowa Hakko Kogyo Kk | método para tratar de um distúrbio de ansiedade, composição, agente para tratar de um distúrbio de ansiedade, e, usos de um composto e de um derivado de xantina |
AU2004303425C1 (en) * | 2003-12-19 | 2010-02-18 | Schering Corporation | Pharmaceutical compositions |
AU2005236059B2 (en) | 2004-04-21 | 2009-01-15 | Schering Corporation | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists |
US7851478B2 (en) * | 2005-06-07 | 2010-12-14 | Kyowa Hakko Kirin Co., Ltd. | Agent for preventing and/or treating movement disorder |
ATE538123T1 (de) | 2005-09-19 | 2012-01-15 | Schering Corp | 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors |
PE20070521A1 (es) | 2005-09-23 | 2007-07-13 | Schering Corp | 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a |
ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
TW200817039A (en) * | 2006-10-06 | 2008-04-16 | Dynamis Therapeutics Inc | Compositions and methods for skin lightening |
EP2125750B1 (de) * | 2007-02-26 | 2014-05-21 | Vitae Pharmaceuticals, Inc. | Zyklische harnstoff- und carbamat-hemmer aus 11-beta-hydroxysteroid-dehydrogenase 1 |
US7691869B2 (en) | 2007-03-30 | 2010-04-06 | King Pharmaceuticals Research And Development, Inc. | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity |
EP2183228B1 (de) * | 2007-07-26 | 2014-08-20 | Vitae Pharmaceuticals, Inc. | ZYKLISCHE 11ß-HYDROXYSTEROID-DEHYDROGENASE-1-HEMMER |
AR069207A1 (es) * | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
CA2708303A1 (en) | 2007-12-11 | 2009-06-18 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
TW200934490A (en) * | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
CA2712500A1 (en) | 2008-01-24 | 2009-07-30 | Vitae Pharmaceuticals, Inc. | Cyclic carbazate and semicarbazide inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
WO2009102428A2 (en) * | 2008-02-11 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1 |
EP2254872A2 (de) * | 2008-02-15 | 2010-12-01 | Vitae Pharmaceuticals, Inc. | Cycloalkyllactamderivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1 |
EP2262811B1 (de) | 2008-03-04 | 2016-04-27 | Merck Sharp & Dohme Corp. | 1,2,4-triazolo[4,3-c]pyrimidin-3-on- und pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-3-onverbindungen zur verwendung als antagonisten des adenosin-a2a-rezeptors |
JP5538356B2 (ja) * | 2008-03-18 | 2014-07-02 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1型の阻害剤 |
CA2722427A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
EP2291370B1 (de) | 2008-05-01 | 2013-11-27 | Vitae Pharmaceuticals, Inc. | Cyclische inhibitoren von 11beta-hydroxysteroiddehydrogenase 1 |
CA2723039A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
JP5451752B2 (ja) * | 2008-05-01 | 2014-03-26 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター |
WO2010010157A2 (en) | 2008-07-25 | 2010-01-28 | Boehringer Ingelheim International Gmbh | INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 |
AU2009274567B2 (en) | 2008-07-25 | 2013-04-04 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1 |
CA2744946A1 (en) | 2009-02-04 | 2010-08-12 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
TW201039034A (en) * | 2009-04-27 | 2010-11-01 | Chunghwa Picture Tubes Ltd | Pixel structure and the method of forming the same |
US8680093B2 (en) | 2009-04-30 | 2014-03-25 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US20100331320A1 (en) * | 2009-04-30 | 2010-12-30 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
WO2011011123A1 (en) | 2009-06-11 | 2011-01-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
WO2011002910A1 (en) | 2009-07-01 | 2011-01-06 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US8933072B2 (en) | 2010-06-16 | 2015-01-13 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
JP5813106B2 (ja) | 2010-06-25 | 2015-11-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝障害の処置のための11−β−HSD1のインヒビターとしてのアザスピロヘキサノン |
AU2011306358B2 (en) * | 2010-09-24 | 2014-08-14 | Impetis Biosciences Ltd. | Fused tricyclic compounds as adenosine receptor antagonist |
EP2635268A1 (de) | 2010-11-02 | 2013-09-11 | Boehringer Ingelheim International GmbH | Pharmazeutische kombinationen zur behandlung von stoffwechselerkrankungen |
WO2015027431A1 (en) | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | 2,2-difluorodioxolo a2a receptor antagonists |
MX2021006329A (es) | 2018-11-30 | 2021-08-11 | Merck Sharp & Dohme Llc | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso. |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0217748B1 (de) | 1985-09-30 | 1991-02-06 | Ciba-Geigy Ag | 2-Substituierte-e-kondensierte[1,5-c]-Pyrimidine, pharmazeutische Zubereitungen und ihre Verwendung |
WO1988002370A1 (en) | 1986-09-30 | 1988-04-07 | Ciba-Geigy Ag | 2-substituted-e-fused-[1,2,4]triazolo[1,5-c]pyrimidines pharmaceutical compositions and uses thereof |
IT1264901B1 (it) * | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
WO1995003806A1 (fr) * | 1993-07-27 | 1995-02-09 | Kyowa Hakko Kogyo Co., Ltd. | Remede contre la maladie de parkinson |
IT1277392B1 (it) | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
IT1291372B1 (it) * | 1997-05-21 | 1999-01-07 | Schering Plough S P A | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
CA2326716C (en) | 1998-04-03 | 2006-12-12 | Otsuka Pharmaceutical Factory, Inc. | Triazolopurine derivative, pharmaceutical composition containing the derivative, adenosine a3 receptor ligand, and remedy for asthma |
AU768520B2 (en) | 1999-09-28 | 2003-12-18 | Otsuka Pharmaceutical Factory, Inc. | Triazolopurine derivatives, drug compositions containing the same and adenosine A3 receptor affinitive agents |
RU2315053C2 (ru) | 2000-05-26 | 2008-01-20 | Шеринг Корпорейшн | ПРОИЗВОДНЫЕ 5-АМИНО-ПИРАЗОЛО-[4,3-е]-1,2,4-ТРИАЗОЛО[1,5-с]ПИРИМИДИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, ПРИМЕНЕНИЕ И СПОСОБЫ ПОЛУЧЕНИЯ ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ |
AU2002346503A1 (en) | 2001-11-30 | 2003-06-17 | Schering Corporation | Adenosine A2a receptor antagonists |
-
2002
- 2002-10-11 AU AU2002340184A patent/AU2002340184B2/en not_active Ceased
- 2002-10-11 AR ARP020103834A patent/AR037243A1/es unknown
- 2002-10-11 IL IL16087802A patent/IL160878A0/xx unknown
- 2002-10-11 KR KR1020047005369A patent/KR100687954B1/ko not_active IP Right Cessation
- 2002-10-11 HU HU0401777A patent/HUP0401777A3/hu unknown
- 2002-10-11 PE PE2002001009A patent/PE20030477A1/es not_active Application Discontinuation
- 2002-10-11 EP EP02778530.2A patent/EP1435960B1/de not_active Expired - Lifetime
- 2002-10-11 CA CA002463598A patent/CA2463598C/en not_active Expired - Fee Related
- 2002-10-11 JP JP2003535799A patent/JP4545437B2/ja not_active Expired - Fee Related
- 2002-10-11 CN CNB028203283A patent/CN100421663C/zh not_active Expired - Fee Related
- 2002-10-11 MX MXPA04003474A patent/MXPA04003474A/es active IP Right Grant
- 2002-10-11 WO PCT/US2002/032630 patent/WO2003032996A1/en active IP Right Grant
- 2002-10-11 NZ NZ531761A patent/NZ531761A/en unknown
- 2002-10-11 MY MYPI20023804A patent/MY124864A/en unknown
- 2002-10-11 US US10/269,754 patent/US6653315B2/en not_active Expired - Lifetime
-
2004
- 2004-04-13 ZA ZA200402812A patent/ZA200402812B/en unknown
-
2008
- 2008-07-25 JP JP2008192667A patent/JP2008297312A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2005506352A (ja) | 2005-03-03 |
HUP0401777A2 (hu) | 2004-12-28 |
CA2463598C (en) | 2009-09-08 |
PE20030477A1 (es) | 2003-06-06 |
KR20050035155A (ko) | 2005-04-15 |
JP4545437B2 (ja) | 2010-09-15 |
KR100687954B1 (ko) | 2007-02-27 |
US20030171381A1 (en) | 2003-09-11 |
CA2463598A1 (en) | 2003-04-24 |
CN1612736A (zh) | 2005-05-04 |
NZ531761A (en) | 2005-10-28 |
HUP0401777A3 (en) | 2008-06-30 |
US6653315B2 (en) | 2003-11-25 |
MY124864A (en) | 2006-07-31 |
EP1435960A1 (de) | 2004-07-14 |
EP1435960B1 (de) | 2014-07-30 |
ZA200402812B (en) | 2005-04-25 |
AR037243A1 (es) | 2004-11-03 |
CN100421663C (zh) | 2008-10-01 |
WO2003032996A1 (en) | 2003-04-24 |
MXPA04003474A (es) | 2004-07-30 |
AU2002340184B2 (en) | 2005-10-06 |
JP2008297312A (ja) | 2008-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL160878A0 (en) | Imidazo (4,3-e)-1,2,4-triazolo (1,5-c) pyrimidines as adenosine a2a receptor antagonists | |
HK1085466A1 (en) | 2-alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c] - pyrimidine adenosine a2a receptor antagonists | |
IL178674A0 (en) | PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS | |
IL220174A0 (en) | 5-AMINO - {PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE}-2-AND 7-SUBSTITUTED DERIVATIVES AS ADENOSINE A2A RECEPTOR INHIBITORS | |
HUP0402270A3 (en) | [1,2,4]triazolo[1,5-c]pyrimidin-5-yl-amines as adenosine a2a receptor antagonists and pharmaceutical compositions containing them | |
HUP0402324A3 (en) | [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine a2a receptor antagonists and pharmaceutical compositions containing them | |
IL158214A0 (en) | 8-heteroaryl xanthine adenosine a2b receptor antagonists | |
HK1063780A1 (en) | Adenosine a2a receptor antagonists | |
IL151849A0 (en) | Pyrido [2,3-d] pyrimidine and pyrimido [4,5-d] pyrimidine nucleosides | |
IL175759A0 (en) | A2b adenosine receptor antagonists | |
PL1608654T3 (pl) | Pochodne 8-podstawionego-6,7,8,9-tetrahydropirymido(1,2-a)pirymidyn-4-onu | |
SI1608653T1 (sl) | Substituirani derivati 8-perfluoroalkil-6,7,8,9-tetrahidropirimido(1,2-a)pirimidin-4-ona | |
SI1430057T1 (sl) | Substituirani 2-piridinil-6,7,8,9-tetrahidropirimido -(1,2-a)pirimidin-4-onski in 7-piridinil-2,3-dihidroimidazo -(1,2-a)pirimidin-5(1H)onski derivati | |
EP1212326A4 (de) | Pyrrolo 2,3-d]pyrimidinnucleosidanaloga | |
HUP0400530A3 (en) | Condensed purine derivatives as a1 adenosine receptor antagonists | |
PL370565A1 (en) | 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists | |
PL1678182T3 (pl) | Sposób wytwarzania podstawionych 5-aminopirazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pirymidyn | |
ZA200608778B (en) | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists | |
TH0401001406A (th) | 2-อัลไคนิล-และ 2-อัลคีนิล-ไพราโซโล-[4,3-e]-1,2,4-ไตรอะโซโล-[1,5-c]-ไพริมิดีน ที่เป็นแอนทาโกนิสท์ของตัวรับอะดีโนซีนA2a | |
AU2002226519A1 (en) | Pyrrolo(2,3-d)pyrimidine and their use as purinergic receptor antagonists | |
AU2002219350A1 (en) | Pyrazolo(3,4-d)pyrimidine derivatives and their use as purinergic receptor antagonists |